Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)

Franck Morschhauser, Ian W. Flinn, Ranjana Advani, Laurie H. Sehn, Catherine Diefenbach, Kathryn Kolibaba, Oliver W. Press, Gilles Salles, Hervé Tilly, Andy I. Chen, Sarit Assouline, Bruce D. Cheson, Martin Dreyling, Anton Hagenbeek, Pier Luigi Zinzani, Surai Jones, Ji Cheng, Dan Lu, Elicia Penuel, Jamie HirataMichael Wenger, Yu Waye Chu, Jeff Sharman

Research output: Contribution to journal › Article › peer-review

180 Scopus citations

Fingerprint

Dive into the research topics of 'Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)'. Together they form a unique fingerprint.

Medicine & Life Sciences